Cancer Institute A national cancer institute
designated cancer center

Allogeneic Transplants

An allogeneic transplant combines the concept of anti-cancer therapy with immunotherapy. The preparative regimen is given to treat your disease, followed by an infusion of hematopoietic (blood forming) cells from your donor's blood or bone marrow. The donor cells provide you with new blood cells and a new immune system. Human Leukocyte Antigens (HLA) are genetic markers of the immune system. The donor cells are obtained from an HLA matched individual. If the donor is a relative, the transplant is called a related donor blood and bone marrow transplant. If the donor is an unrelated individual, the transplant is called an unrelated donor (URD) blood and bone marrow transplant.

The intensity of the preparative regimen – the therapy administered before you receive the donor's cells – can vary. The preparative regimen ranges in intensity from high dose preparative regimens to reduced intensity preparative regimens.

Stanford Medicine Resources:

Footer Links: